Trial Profile
A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV).
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Candesartan cilexetil
- Indications Heart failure
- Focus Biomarker; Pharmacodynamics
- Acronyms OLMEBNP
- Sponsors Daiichi Sankyo Europe
- 01 Apr 2022 This trial has been completed in France (End Date: 12 Nov 2008) according to European Clinical Trials Database record.
- 31 Mar 2022 This trial has been completed in Czech Republic (End Date: 12 Nov 2008) according to European Clinical Trials Database record.
- 06 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.